openPR Logo
Press release

Androgenetic Alopecia Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years | Top Key Players are RepliCel Life Sciences Inc., Almirall, Samumed, LLC, Brickell Biotech, Inc., Aclaris Therapeutics, Inc.

06-06-2019 01:16 PM CET | Health & Medicine

Press release from: Pharma Proff

Androgenetic Alopecia Therapeutics Pipeline to Witness

Androgenetic alopecia is a genetic disorder of patterned hair loss that affects both men and women. The disorder shortens hair growth cycle due to excess of androgen, which eventually delays hair growth. Some of the major symptoms include gradual recession of frontal hairline, increased hair fall, bitemporal recession of hair, and thinning of the hair. The symptoms start appearing at the age of 20 and are seen to be prominent in people aged 40 years and above. The disorder leads to hair thinning near crown region, and maybe caused due to various genetic as well as environmental factors. The disorder can also occur due to hormonal imbalance, improper functioning of androgen hormones, poor diet, and excessive smoking.
Download the sample report at:

Androgenetic alopecia can diagnose with the help of blood tests, thyroid tests, biopsy, transferrin iron-binding capacity, Norwood Hamilton Scale assessment in men, and dehydroepiandrosterone sulfate (DHEAS) and testosterone analysis in women. The disorder can be treated by surgical transplantation, medical procedures, and low-level light therapy.
Propecia is one of the key U.S. Food and Drug Administration (USFDA) approved drugs, developed by Merck & Co. Inc., for the treatment of androgenetic alopecia in men.

Browse Detailed Report at:

According to the research, many drugs being developed for androgenetic alopecia, which are administered topically. It has been found that topical route of administration is easy to use, non-invasive, and ensures high level of patient satisfaction.
There are several companies which have shown positive results of clinical trials. For instance, in February 2019, Cassiopea SpA announced effective result of Phase II clinical trial of Breezula for treatment of androgenetic alopecia.
It has been observed that many pharmaceutical companies are developing new and improved technologies for the development of androgenetic alopecia therapeutics. These technologies play an important role in the drug development by helping the companies to develop more specific and effective targeted therapies. For instance, RepliCel Life Sciences is using its proprietary cell therapy technology to develop therapeutic candidates for pattern baldness and other disorders. It utilizes dermal sheath cup cells, which induce the growth of cells in the area of baldness.

Make enquiry before purchase at:

Samumed LLC, Brickell Biotech Inc., Aclaris Therapeutics Inc., Cassiopea S.p.A, Kerastem Technologies LLC, Almirall S.A., and RepliCel Life Sciences are the major players involved in the development of drug candidates for the treatment of androgenetic alopecia.

Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Androgenetic Alopecia Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years | Top Key Players are RepliCel Life Sciences Inc., Almirall, Samumed, LLC, Brickell Biotech, Inc., Aclaris Therapeutics, Inc. here

News-ID: 1766694 • Views: 1912

More Releases from Pharma Proff

Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates. IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates. Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome. Download the sample report at: Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances

All 5 Releases

More Releases for Androgenetic

Minoxidil Market to showcase significant growth from healthcare application | By …
An increase in the prevalence of hair loss disorders and the increasing consumer awareness regarding the availability of treatments to cure hair loss issues has positively influenced global minoxidil market trends. Enhanced marketing efforts undertaken to encourage the use of novel hair growth products which has helped expand the reach of minoxidil worldwide. Request a sample of this research report @ A gradual economic improvement in both developed and developing
Alopecia Treatment Market Frequent Launch, Approvals, and Robust Pipeline By Lea …
Product launches, approvals, and robust pipeline of novel products is expected to be the major driver of growth of the global alopecia treatment market. For instance, in 2016, Cellmid Limited, a wholly owned subsidiary, Advangen Limited launched new hair loss product évolis in U.S. market. In May 2018, Histogen, Inc., received approval of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to study its
Home-Use Beauty Devices Market Opportunities by Types, Demand, Top Manufactures …
The market is mainly driven by increasing inclination of consumers toward easy-to-use home-use beauty devices, rising prevalence of skin diseases, growing appearance consciousness in people and awareness about these devices, expanding product portfolio of market players, and surge in disposable income. Access Detailed Report Summary: Based on type, the home-use beauty devices market for anti-aging is expected to reach $3.9 billion by 2023, registering a CAGR of 21.7% during the forecast
Alopecia Treatment Market Analysis of Valuable Foresights on How Alopecia Treatm …
Alopecia also called as hair loss or baldness is very common condition affecting people across the globe. Alopecia can affect people of all gender and at any stage of life, it generally it affects mid-aged generation. For instance, according the data published by Arch Argent Pediatr in 2017, the prevalence of Alopecia areata is high in the age group of 10 and 25 years and around 60% of people under
Hair Transplant Market Complete Growth Analysis For Lumenis, Restoration Robotic …
Market Study Report recently introduced new title on “2018-2024 Hair Transplant Market Report” that provides an in-depth overview of industry and competitive landscape, covering multiple market segments and elaborates market outlook and status to 2024. Hair transplant stem cell therapy valued at over USD 122.9 million in the year 2017 and is expected to grow at significant rate. According to National Institutes of Health, Androgenetic alopecia is the most common type
Alopecia Treatment Market - Global Forecast to 2026
Alopecia also called as hair-loss or baldness is a medical condition that refers to loss of hairs from head or any part of the body. The condition can occur in both male and female and at any age. There are five major type of alopecia namely; alopecia areata, androgenic alopecia, ciatricial alopecia, traction alopecia, and alopecia totalis. Alopecia areata is a common autoimmune disorder in which the immune system of